COUC 691 QUIZ TREATMENT OF CORMID
DISORDERS| UPDATED WITH COMPLETE SOLUTION |
RATED A+ | LIBERTY UNIVERSITY 2026/2027
90 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
COUC 691 QUIZ TREATMENT OF CORMID DISORDERS| UPDATED WITH COMPLETE SOLUTION | RATED
A+ | LIBERTY UNIVERSITY 2026/2027. It contains 90 carefully selected questions that reflect the most current
exam content and testing strategies. Each question is accompanied by a correct answer and a detailed rationale
that explains the underlying pathophysiology, pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 90 Questions
Foundations - Application - COUC 691 Treatment OF Cormid Disorders Updated WITH Complete Solution
Rated A Liberty University 2026/2027 Counseling AND Psychopathology Graduate
All answers with rationales
,Table of Contents
Content Area Questions Key Topics
Diagnosis AND Classification 1-15 Disorder, Comorbid, Critical, Generalized Anxiety, Evidence
OF Comorbid Disorders
Epidemiology AND Etiology 16-30 Disorder, Comorbid, Treatment, Alcohol, Medication
OF Comorbid Conditions
Assessment AND Screening 31-45 Disorder, Comorbid, Treatment, Depressive, Anxiety
Tools FOR Comorbidity
Treatment Planning AND 46-60 Disorder, Anxiety, Weeks, Co-occurring, Panic
Integrated CARE Approaches
Pharmacological 61-75 Disorder, Comorbid, Treatment, Combination, Depression
Interventions FOR Comorbid
Disorders
Psychotherapeutic 76-90 Disorder, Evidence, Current, Stabilized, According
Interventions CBT DBT ETC
TOTAL 90 All questions include answers and detailed rationales
,Section A - Diagnosis AND Classification OF Comorbid
Disorders
Q1.
A patient with treatment-resistant depression and comorbid generalized anxiety disorder
has failed two SSRIs. Which augmentation strategy is most supported by current evidence
for this dual diagnosis?
A. Add aripiprazole 2 mg daily B. Switch to venlafaxine XR 150 mg daily
C. Add pregabalin 150 mg daily D. Add buspirone 15 mg twice daily
Correct: A - Add aripiprazole 2 mg daily
Rationale:Aripiprazole is FDA-approved as an adjunct for major depressive disorder and has
shown efficacy in reducing anxiety symptoms in patients with comorbid anxiety. Venlafaxine is
a reasonable switch but not augmentation. Pregabalin is approved for GAD but not as an
antidepressant adjunct. Buspirone has limited efficacy in treatment-resistant depression.
Why the other answers are wrong:
B. Switching to venlafaxine is a reasonable alternative but not the best-supported augmentation
strategy for treatment-resistant depression.
C. Pregabalin is not approved for depression and lacks evidence as an antidepressant
augmentation.
D. Buspirone has weak evidence in treatment-resistant depression and is primarily for anxiety.
Reference: Stahl, S. M. (2026). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 5.
Q2.
In a patient with borderline personality disorder and comorbid PTSD, which treatment
approach is currently recommended as first-line?
A. Prolonged exposure therapy alone B. Dialectical behavior therapy (DBT)
adapted for PTSD
C. Cognitive processing therapy (CPT) D. EMDR therapy
alone
Correct: B - Dialectical behavior therapy (DBT) adapted for PTSD
Rationale:DBT adapted for PTSD (DBT-PTSD) is specifically designed for patients with BPD
and comorbid PTSD, addressing both emotion dysregulation and trauma. Prolonged
exposure and CPT may be effective for PTSD but can destabilize patients with severe BPD
symptoms. EMDR lacks sufficient evidence in this comorbid population.
Why the other answers are wrong:
A. Prolonged exposure may exacerbate emotion dysregulation in BPD without first addressing
Page 3
, Section A - Diagnosis AND Classification OF Comorbid Disorders
skills.
C. CPT alone may not address the self-harm and interpersonal instability characteristic of BPD.
D. EMDR has limited evidence for complex PTSD with BPD and is not considered first-line.
Reference: Bohus, M., et al. (2020). DBT-PTSD for patients with BPD and PTSD. Lancet Psychiatry.
Q3.
Which of the following best explains the rationale for using quetiapine as an adjunct in
treating comorbid major depressive disorder and chronic insomnia?
A. It selectively targets 5-HT2A receptors to B. Its antihistaminergic and 5-HT2A
improve sleep architecture without metabolic antagonism at low doses improves sleep
side effects. and augments antidepressant response.
C. It has a short half-life that minimizes D. It is the only atypical antipsychotic with
daytime sedation while enhancing FDA approval for both depression and
slow-wave sleep. insomnia.
Correct: B - Its antihistaminergic and 5-HT2A antagonism at low doses improves sleep
and augments antidepressant response.
Rationale:Quetiapine at low doses blocks histamine H1 and 5-HT2A receptors, promoting
sleep and augmenting antidepressant effects. It is not selective for 5-HT2A and has metabolic
side effects. Its half-life is not particularly short, and it is not FDA-approved for insomnia.
Why the other answers are wrong:
A. Quetiapine has broad receptor binding, including H1 and D2, and is associated with
metabolic side effects.
C. Quetiapine's half-life is moderate, not short, and it can cause daytime sedation.
D. No atypical antipsychotic is FDA-approved for insomnia.
Reference: Lehne, R. A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 16.
Q4.
A patient with bipolar I disorder and comorbid alcohol use disorder is being treated with
lithium. Which consideration is most critical regarding this comorbidity?
A. Lithium may reduce alcohol cravings, B. Alcohol-induced dehydration can
making it a dual-purpose agent. increase lithium toxicity risk.
C. Lithium is contraindicated with alcohol D. Disulfiram is the preferred adjunct to
due to hepatotoxicity. lithium for this patient.
Correct: B - Alcohol-induced dehydration can increase lithium toxicity risk.
Rationale:Alcohol can cause dehydration, leading to increased lithium levels and toxicity.
Lithium does not reduce alcohol cravings; it is not hepatotoxic. Disulfiram may interact with
lithium and is not preferred.
Why the other answers are wrong:
Page 4
DISORDERS| UPDATED WITH COMPLETE SOLUTION |
RATED A+ | LIBERTY UNIVERSITY 2026/2027
90 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
COUC 691 QUIZ TREATMENT OF CORMID DISORDERS| UPDATED WITH COMPLETE SOLUTION | RATED
A+ | LIBERTY UNIVERSITY 2026/2027. It contains 90 carefully selected questions that reflect the most current
exam content and testing strategies. Each question is accompanied by a correct answer and a detailed rationale
that explains the underlying pathophysiology, pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 90 Questions
Foundations - Application - COUC 691 Treatment OF Cormid Disorders Updated WITH Complete Solution
Rated A Liberty University 2026/2027 Counseling AND Psychopathology Graduate
All answers with rationales
,Table of Contents
Content Area Questions Key Topics
Diagnosis AND Classification 1-15 Disorder, Comorbid, Critical, Generalized Anxiety, Evidence
OF Comorbid Disorders
Epidemiology AND Etiology 16-30 Disorder, Comorbid, Treatment, Alcohol, Medication
OF Comorbid Conditions
Assessment AND Screening 31-45 Disorder, Comorbid, Treatment, Depressive, Anxiety
Tools FOR Comorbidity
Treatment Planning AND 46-60 Disorder, Anxiety, Weeks, Co-occurring, Panic
Integrated CARE Approaches
Pharmacological 61-75 Disorder, Comorbid, Treatment, Combination, Depression
Interventions FOR Comorbid
Disorders
Psychotherapeutic 76-90 Disorder, Evidence, Current, Stabilized, According
Interventions CBT DBT ETC
TOTAL 90 All questions include answers and detailed rationales
,Section A - Diagnosis AND Classification OF Comorbid
Disorders
Q1.
A patient with treatment-resistant depression and comorbid generalized anxiety disorder
has failed two SSRIs. Which augmentation strategy is most supported by current evidence
for this dual diagnosis?
A. Add aripiprazole 2 mg daily B. Switch to venlafaxine XR 150 mg daily
C. Add pregabalin 150 mg daily D. Add buspirone 15 mg twice daily
Correct: A - Add aripiprazole 2 mg daily
Rationale:Aripiprazole is FDA-approved as an adjunct for major depressive disorder and has
shown efficacy in reducing anxiety symptoms in patients with comorbid anxiety. Venlafaxine is
a reasonable switch but not augmentation. Pregabalin is approved for GAD but not as an
antidepressant adjunct. Buspirone has limited efficacy in treatment-resistant depression.
Why the other answers are wrong:
B. Switching to venlafaxine is a reasonable alternative but not the best-supported augmentation
strategy for treatment-resistant depression.
C. Pregabalin is not approved for depression and lacks evidence as an antidepressant
augmentation.
D. Buspirone has weak evidence in treatment-resistant depression and is primarily for anxiety.
Reference: Stahl, S. M. (2026). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 5.
Q2.
In a patient with borderline personality disorder and comorbid PTSD, which treatment
approach is currently recommended as first-line?
A. Prolonged exposure therapy alone B. Dialectical behavior therapy (DBT)
adapted for PTSD
C. Cognitive processing therapy (CPT) D. EMDR therapy
alone
Correct: B - Dialectical behavior therapy (DBT) adapted for PTSD
Rationale:DBT adapted for PTSD (DBT-PTSD) is specifically designed for patients with BPD
and comorbid PTSD, addressing both emotion dysregulation and trauma. Prolonged
exposure and CPT may be effective for PTSD but can destabilize patients with severe BPD
symptoms. EMDR lacks sufficient evidence in this comorbid population.
Why the other answers are wrong:
A. Prolonged exposure may exacerbate emotion dysregulation in BPD without first addressing
Page 3
, Section A - Diagnosis AND Classification OF Comorbid Disorders
skills.
C. CPT alone may not address the self-harm and interpersonal instability characteristic of BPD.
D. EMDR has limited evidence for complex PTSD with BPD and is not considered first-line.
Reference: Bohus, M., et al. (2020). DBT-PTSD for patients with BPD and PTSD. Lancet Psychiatry.
Q3.
Which of the following best explains the rationale for using quetiapine as an adjunct in
treating comorbid major depressive disorder and chronic insomnia?
A. It selectively targets 5-HT2A receptors to B. Its antihistaminergic and 5-HT2A
improve sleep architecture without metabolic antagonism at low doses improves sleep
side effects. and augments antidepressant response.
C. It has a short half-life that minimizes D. It is the only atypical antipsychotic with
daytime sedation while enhancing FDA approval for both depression and
slow-wave sleep. insomnia.
Correct: B - Its antihistaminergic and 5-HT2A antagonism at low doses improves sleep
and augments antidepressant response.
Rationale:Quetiapine at low doses blocks histamine H1 and 5-HT2A receptors, promoting
sleep and augmenting antidepressant effects. It is not selective for 5-HT2A and has metabolic
side effects. Its half-life is not particularly short, and it is not FDA-approved for insomnia.
Why the other answers are wrong:
A. Quetiapine has broad receptor binding, including H1 and D2, and is associated with
metabolic side effects.
C. Quetiapine's half-life is moderate, not short, and it can cause daytime sedation.
D. No atypical antipsychotic is FDA-approved for insomnia.
Reference: Lehne, R. A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 16.
Q4.
A patient with bipolar I disorder and comorbid alcohol use disorder is being treated with
lithium. Which consideration is most critical regarding this comorbidity?
A. Lithium may reduce alcohol cravings, B. Alcohol-induced dehydration can
making it a dual-purpose agent. increase lithium toxicity risk.
C. Lithium is contraindicated with alcohol D. Disulfiram is the preferred adjunct to
due to hepatotoxicity. lithium for this patient.
Correct: B - Alcohol-induced dehydration can increase lithium toxicity risk.
Rationale:Alcohol can cause dehydration, leading to increased lithium levels and toxicity.
Lithium does not reduce alcohol cravings; it is not hepatotoxic. Disulfiram may interact with
lithium and is not preferred.
Why the other answers are wrong:
Page 4
